首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3195篇
  免费   232篇
  国内免费   423篇
  2024年   5篇
  2023年   84篇
  2022年   139篇
  2021年   139篇
  2020年   125篇
  2019年   153篇
  2018年   105篇
  2017年   111篇
  2016年   102篇
  2015年   152篇
  2014年   193篇
  2013年   234篇
  2012年   129篇
  2011年   192篇
  2010年   141篇
  2009年   179篇
  2008年   171篇
  2007年   185篇
  2006年   203篇
  2005年   169篇
  2004年   149篇
  2003年   131篇
  2002年   103篇
  2001年   95篇
  2000年   73篇
  1999年   72篇
  1998年   48篇
  1997年   50篇
  1996年   35篇
  1995年   26篇
  1994年   29篇
  1993年   30篇
  1992年   23篇
  1991年   22篇
  1990年   10篇
  1989年   7篇
  1988年   5篇
  1987年   4篇
  1986年   2篇
  1985年   7篇
  1984年   6篇
  1983年   1篇
  1982年   1篇
  1981年   3篇
  1979年   1篇
  1978年   3篇
  1975年   1篇
  1974年   1篇
  1972年   1篇
排序方式: 共有3850条查询结果,搜索用时 93 毫秒
1.
2.
Summary Under the ?Bois plus? scheme, the CTBA is currently developing a third party certification, based on the Scrivener law, with the aim of defending the consumers' interests. At this early stage, wood preservatives and treated wood are checked for the efficacy of treatments in order to ensure the stability and security of works in buildings and civil engineering. According to the different classes of risks in service, ?Bois plus? provides the most adeguate level of protection. In the close future, the industry is planning to incorporate, with the help of the CTBA and experts, health criteria within the frame of the ?Bois plus? certification scheme. The means could beSafety indexes, which are objectives of quality for professionals.Safety indexes are concentrations of substances in wood which can be taken as safe for humans and the general environment, while still toxic for the wood pests. This attractive experience aims to make with the brandname ?Bois plus? a synonym of efficacy and safety. This approach meets the essential requirements 1, 3, 4 of the 89/106 EEC directive: mechanical resistance and stability/hygiene, health and environment/safety in use.  相似文献   
3.
Four monoepitopic MAPs (MAP A, B, C and E) and one bis-diepitopic MAP B-E derived fromthe primary sequence of Schistosoma mansoni glyceraldehyde 3-phosphate dehydrogenase, previously tested in BALB/c mice, were examined for their immunogenicity and protective capacity in C57BL/6 mice. Despite multimerization into MAPs, MAP Aand MAP C were poorly immunogenic. In contrast toBALB/c mice, MAP E was non-immunogenic in C57BL/6 mice. Peptide B in the form of MAP B orbis-diepitopic MAPB-E elicited immune responses in C57BL/6 mice that were associated with a significant decrease in worm burden. The MAPs were prepared by the stepwise solid-phase peptide synthesis using Boc/Bzl chemistry, successfully purified on the RP-HPLC column and characterized by RP-HPLC, HPCE and MALDI-TOF MS techniques. A general strategy for MAPs purification is discussed here and the purification of MAP Band MAP E is documented in detail.  相似文献   
4.
Further studies of human whole-body radiofrequency (RF) absorption rates were carried out using a TEM-cell exposure system. Experiments were done at one frequency near the grounded resonance frequency (approximately 40 MHz), and at several below-resonance frequencies. Absorption rates are small for the K and H orientations of the body, even when grounded. For the body trunk in an E orientation, the absorption rate of a sitting person is about half of the rate for the same person standing with arms at the sides; the latter in turn is about half the rate for the same subject standing with arms over the head. Two-body interactions cause no increase in absorption rates for grounded people. They do, however, increase the absorption rates for subjects in an E orientation in free space; the largest interaction occurs when one subject is lambda/2 behind the other (as seen by the incident wave). When these results are applied to practical occupational exposure situations, the whole-body specific absorption rate does not exceed the ANSI limit of 0.4 W/kg for exposures permitted by the ANSI standard (C95.1-1982) at frequencies from 7 to 40 MHz.  相似文献   
5.
伤寒Vi多糖菌苗接种反应观察   总被引:3,自引:1,他引:2  
本文报告了对我国首次成功的伤寒Vi多糖菌苗进行人体接种反应观察结果,接种对象为20至54岁无伤寒病史,近年无伤寒菌苗接种史的健康人,共60名,以完全随机的方法分为两组,实验组注射30μgVi多糖菌苗,对照组注射Vi多糖菌苗的稀释液。其结果30名Vi多糖菌苗接种者注射后体温无中重反应发生,局部红肿仅有1例中反应。注射后对血压、心律没有影响。红细胞计数,白细胞计数均在正常范围,与接种前相比,无显著差异  相似文献   
6.
对79名HBV标志阴性少年人群,以乙肝疫苗10μg×3的免疫剂量和0、1、2月的免疫程序进行接种,对其抗-HBs免疫应答和临床保护效果作了为期7年的定人随访。结果表明,抗-HBs阳转率在免后三个月时为100%,均值为3084MIU/ml。至免后84个月时疫苗接受者中仍有55.7%的抗-HBs水平≥10MIU/ml。6例检出抗-HBs,其中5例的抗-HBs持续处于高水平。全部观察对象无一例检出HBsAg或发生临床肝炎。少年接种乙肝血源疫苗至少7年内可具有保护性抗体。故在此期内不需加强免疫。  相似文献   
7.
不同月龄婴儿接种DTP后血清中百日咳抗体水平的观测   总被引:2,自引:1,他引:1  
本文对比观察了213例2月龄、3月龄婴儿接种DTP后百日咳抗体水平的变化,探讨了母传抗体对免后抗体增长的影响。结果表明2月龄、3月龄婴儿DTP免疫后1个月和3个月血清中百日咳抗体达保护水平的百分率无显著性差异(x ̄2=0.036,p>0.9;x ̄2=0.327,p>0.5),免后1个月抗体GMT无显著性差异(t=0.17,p>0.5),免后3个月抗体GMT3月龄组高于2月龄组(t=2.22,p<0.05)。我们还发现免前抗体水平与免后1个月GMT虽有负相关(r=—0,754)的倾向,但总体上对抑制免后抗体应答不明显,因而建议将儿童DTP基础免疫的起始月龄提前至2月龄进行。  相似文献   
8.
Storage at 6.5°C under moderate vacuum effectively prevented growth of Aeromonas hydrophila on chicory endive, but had only a limited inhibitory effect on the growth of the organism on mung bean sprouts. Growth of Listeria monocytogenes on chicory endive was strongly stimulated under these conditions, whereas it was decreased on mung-bean sprouts.  相似文献   
9.
Porins were prepared from smooth strain of Salmonella typhi 0–901 and chemotype of rough mutant of S. typhimurium Ra-30. Mice were immunized with both the porin preparations in different groups and challenged with S. typhimurium LT2–71 and S. enteritidis SH-1269. Porin immunized mice showed significant protection (P <0.01) against challenge with homologous as well as heterologous strains. Hence, the use of porins may be attempted in future to protect against salmonellosis.  相似文献   
10.
Several groups have reported protection against experimental SIV infection in macaques immunized with a whole inactivated virus vaccine. The aim of the current study was to investigate whether five macaques vaccinated with whole inactivated SIV and previously shown to be protected against challenge with two divergent strains of SIV grown on human cells could resist challenge with a subsequent homologous SIV grown on macaque cells. We show here that this same vaccine did not protect when the challenge virus was grown on primary cells of monkey origin.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号